Open access
Open access
Powered by Google Translator Translator

Infectious Diseases (all articles)

Updated NIH COVID-19 Treatment Guidelines: Therapeutic management of nonhospitalized adults with COVID-19.

2 Feb, 2022 | 08:50h | UTC

Therapeutic Management of Nonhospitalized Adults With COVID-19 – NIH COVID-19 Treatment Guidelines

 

Commentary on Twitter

 

Editorial: Menstruation and Covid-19 vaccination.

2 Feb, 2022 | 08:46h | UTC

Menstruation and covid-19 vaccination – The BMJ

News Release: New studies provide reassuring data on menstrual changes after covid-19 vaccination – BMJ

 

Commentary on Twitter

 

Ten billion COVID vaccinations: world hits new milestone.

2 Feb, 2022 | 08:48h | UTC

Ten billion COVID vaccinations: world hits new milestone – Nature

 

Commentary on Twitter

 

As Denmark scraps COVID restrictions, WHO urges caution.

2 Feb, 2022 | 08:47h | UTC

As Denmark Scraps COVID Restrictions, WHO Urges Caution – Health Policy Watch

Related: Despite the ongoing spread of Omicron, some European countries have decided to lift Covid-19 restrictions.

 

Short Review | Hypersensitivity reactions to vaccines in children: from measles to SARS-CoV-2.

2 Feb, 2022 | 08:13h | UTC

Hypersensitivity reactions to vaccines in children: from measles to SARS-CoV-2 – Pediatric Allergy and Immunology

Commentary: Vaccine hypersensitivity in children – News Medical

 

Observational study suggests Ceftaroline has comparable efficacy vs. Daptomycin for the treatment of Methicillin-Resistant Staphylococcus aureus bloodstream infection.

2 Feb, 2022 | 08:07h | UTC

Multicenter Cohort Study of Ceftaroline versus Daptomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection – Open Forum Infectious Diseases

 

Commentary on Twitter

 

[Preprint] Study suggests SARS-CoV-2 Omicron subvariants BA.2 is even more transmissible than the original variant.

1 Feb, 2022 | 08:56h | UTC

Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households – medRxiv

Commentaries:

Study suggests BA.2 COVID-19 subvariant more contagious – CIDRAP

‘Stealth Omicron’ spreads more than original strain: study – MedicalXpress

The new Omicron subtype BA.2 could prolong the current wave of COVID-19 infection, scientists say- Business Insider

 

Commentary from the author on Twitter (thread – click for more)

 

Does the world need an Omicron vaccine? What researchers say.

1 Feb, 2022 | 08:53h | UTC

Does the world need an Omicron vaccine? What researchers say – Nature

 

Will Omicron end the pandemic? Here’s what experts say.

1 Feb, 2022 | 08:54h | UTC

Will Omicron end the pandemic? Here’s what experts say – Nature

 

Randomized trials on non-pharmaceutical interventions for COVID-19 as of August 2021: a scoping review.

1 Feb, 2022 | 08:51h | UTC

Randomised trials on non-pharmaceutical interventions for COVID-19 as of August 2021: a scoping review – BMJ Evidence-Based Medicine

Related:

Study ranks the most effective non-pharmaceutical interventions for reducing COVID-19 spread

Effect of Non-pharmaceutical Interventions to Contain COVID-19 in China

 

Commentary from the author on Twitter (thread – click for more)

 

The extraordinary success of Covid-19 vaccines, in two charts.

1 Feb, 2022 | 08:48h | UTC

The extraordinary success of Covid-19 vaccines, in two charts – Vox

 

M-A: The diagnostic accuracy of syndromic management for genital ulcer disease.

1 Feb, 2022 | 08:12h | UTC

The Diagnostic Accuracy of Syndromic Management for Genital Ulcer Disease: A Systematic Review and Meta-Analysis – Frontiers in Medicine

 

Registry study in Denmark found an increased bleeding risk with the association of systemic Fluconazole and Apixaban (OR 3.5; 95% CI, 1.4-10.6).

1 Feb, 2022 | 08:13h | UTC

Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran – American Journal of Medicine

 

Studies show parental vaccination provided indirect protection of children from SARS-CoV-2 infection during the Delta wave.

30 Jan, 2022 | 14:52h | UTC

Indirect protection of children from SARS-CoV-2 infection through parental vaccination – Science

See also: Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel – Science

Commentary: COVID vaccine markedly cuts household transmission, studies show – CIDRAP

 

Commentary on Twitter

 

A nationwide cohort study in Denmark showed Long Covid in children is rare and mainly of short duration.

30 Jan, 2022 | 14:40h | UTC

Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study – European Journal of Pediatrics

Related:

Editorial | Long covid in children and adolescents – “Risk appears low, but many questions remain”.

M-A: Persistent symptoms following SARS-CoV-2 infection among children and young people – “Higher study quality was associated with lower prevalence of all symptoms, except loss of smell and cognitive symptoms”.

Review: Long COVID symptoms in children rarely persist beyond three months.

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Do kids get long COVID? And how often? A pediatrician looks at the data – Children also get Long Covid, but much less often than adults.

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

 

Commentary on Twitter

 

Observational analysis in Lombardy, Italy, showed a gradual decrease in protection against SARS-CoV-2 clinical outcomes after the second dose of vaccine.

30 Jan, 2022 | 14:51h | UTC

Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy – The Lancet Infectious Diseases

Commentary: COVID-19 vaccine: what are we doing and what should we do? – The Lancet Infectious Diseases

 

FDA halts use of antibody drugs that don’t work vs. Omicron.

30 Jan, 2022 | 14:35h | UTC

FDA halts use of antibody drugs that don’t work vs. omicron – Associated Press

Related: Lab study shows new antiviral pills maintain efficacy against Omicron, but antibody drugs are substantially less effective.

 

Despite the ongoing spread of Omicron, some European countries have decided to lift Covid-19 restrictions.

30 Jan, 2022 | 14:37h | UTC

England lifts COVID restrictions as omicron threat recedes – Associated Press

Denmark confirms plan to lift Covid-19 restrictions on February 1st – The Local dk

Netherlands lifts toughest Covid curbs with Denmark and France set to follow – The Guardian

Denmark will lift nearly ALL Covid restrictions within days and return to ‘life as we knew it before corona’ after vaccine programme proved a ‘super-weapon’ – despite soaring cases – Daily Mail

 

Commentary on Twitter

 

Myocarditis after BNT162b2 vaccination in Israeli adolescents.

30 Jan, 2022 | 14:34h | UTC

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents – New England Journal of Medicine

Related:

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

 

Commentary on Twitter

 

European Consensus: Prevention of periprosthetic joint infection in total hip and knee replacement.

30 Jan, 2022 | 14:17h | UTC

Prevention of Periprosthetic Joint Infection in Total Hip and Knee Replacement: One European Consensus – Journal of Clinical Medicine

 

M-A: Helicobacter pylori eradication may result in modest improvement in functional dyspepsia.

30 Jan, 2022 | 14:01h | UTC

Efficacy of Helicobacter pylori eradication therapy for functional dyspepsia: updated systematic review and meta-analysis – Gut (link to abstract – $ for full-text)

Commentary: H. pylori eradication therapy may lead to better outcomes for functional dyspepsia – ACP Gastroenterology

 

Perspective | Where do we stand with Omicron? The data, the math, the patterns, and the exit.

28 Jan, 2022 | 08:39h | UTC

Where do we stand with Omicron? – by Dr. Eric Topol

 

Commentary on Twitter

 

Clinical characteristics and outcomes of patients with COVID-19–Associated Acute Respiratory Distress Syndrome who underwent lung transplant.

28 Jan, 2022 | 08:41h | UTC

Clinical Characteristics and Outcomes of Patients With COVID-19–Associated Acute Respiratory Distress Syndrome Who Underwent Lung Transplant – JAMA

Related: Cases of lung transplantation for Covid-19–related respiratory failure in the US were associated with a three-month survival of 95.6%.

 

RCT: Hyperimmune immunoglobulin did not improve outcomes in hospitalized patients with COVID-19.

28 Jan, 2022 | 08:42h | UTC

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial – The Lancet

Commentaries:

High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19 – The Lancet

Hyperimmune intravenous immunoglobulin does not improve outcomes for adults hospitalized with COVID-19 – NIH News Releases

 

After Omicron, some scientists foresee ‘a period of quiet’.

28 Jan, 2022 | 08:36h | UTC

After Omicron, some scientists foresee ‘a period of quiet’ – Science

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.